A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...
Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.
Trial results show setrusumab reduces the incidence of fracture and increases bone density and formation. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Maybe you heard about it after watching the Samuel L. Jackson movie "Unbreakable." Or maybe after binging Season 11 of "Grey's Anatomy." Or maybe the words "osteogenesis imperfecta," or "OI," don't ...
Osteogenesis imperfecta type 3 is an inherited (genetic) bone disorder that is present at birth, according to John Hopkins Medicine, which notes that it is a lifelong condition. Furthermore, there is ...
There are no FDA-approved therapies for the treatment of OI.
Zacks Investment Research on MSN
Rare, MREO tank as osteogenesis study fails to meet primary endpoint
Shares of Ultragenyx Pharmaceutical RARE and Mereo BioPharma MREO plunged 42.3% and 87.6%, respectively, on Dec. 29 after the companies announced disappointing data from the phase III Orbit and Cosmic ...
A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback